Brief: The Scottish Medicines Consortium Recommends Use Of Hansa Biopharma's Idefirix As Desensitization Treatment For Highly Sensitized Kidney Transplant Patients
12/09/2022 19:25
Sept 12 (Reuters) - Hansa Biopharma AB HNSA.ST :
* THE SCOTTISH MEDICINES CONSORTIUM (SMC) RECOMMENDS USE OF HANSA BIOPHARMA'S IDEFIRIX ®
(IMLIFIDASE) AS DESENSITIZATION TREATMENT FOR HIGHLY SENSITIZED KIDNEY TRANSPLANT PATIENTS
Source text for Eikon: ID:nPn8fGJ1da
Further company coverage: HNSA.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS